K-Ras(G12C) inhibitor 6
K-Ras(G12C) inhibitor 6 is an irreversible inhibitor of oncogenic K-Ras(G12C),[1] subverting the native nucleotide preference to favour GDP over GTP. Its family of inhibitors allosterically control GTP affinity and effector interactions by fitting inside a "pocket", or binding site, of mutant K-Ras.
![]() | |
Names | |
---|---|
Preferred IUPAC name
N-{1-[(2,4-Dichlorophenoxy)acetyl]piperidin-4-yl}-4-sulfanylbutanamide | |
Identifiers | |
3D model (JSmol) |
|
ChemSpider | |
PubChem CID |
|
| |
| |
Properties | |
C17H22Cl2N2O3S | |
Molar mass | 405.33 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references |
Investigators and pathologists previously thought that K-Ras is undruggable.[2] However, Kevan M. Shokat and his colleagues, in the Howard Hughes Medical Institute (HHMI) at the University of California, recently reported a novel discovery of "Achilles heel" on K-RAs, and believed that it has real translational implications for patients with K-RAs mutation.
References
- "K-Ras(G12C) inhibitor 6". selleckchem.com.
- "Researchers identify new mechanism to target 'undruggable' cancer gene". www.sciencedaily.com. Retrieved 2017-01-17.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.